Abigail B Abrahams

Dr. Abigail B Abrahams

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2024 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
AAAbigail B Abrahams
Abigail B Abrahams
ABAmy C Beckenstrom
Amy C Beckenstrom
MBMichael Browning
Michael Browning
RDRebecca Dias
Rebecca Dias
GGGuy M Goodwin
Guy M Goodwin
GDGerard R Dawson
Gerard R Dawson

28 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SWSara Wong
Sara Wong
ABAlexander D. Brown
Alexander D. Brown
AAAbigail B Abrahams
Abigail B Abrahams
ANAn Nisaa Nurzak
An Nisaa Nurzak
HEHoda Eltaher
Hoda Eltaher
MKMadeleine Victoria King
Madeleine Victoria King
Background/Objectives: Peptide-based treatments represent an expanding area and require innovative approaches to enhance bioavailability. Combination with cell-penetrating peptides (CPPs) is an attractive strategy to improve non-invasive delivery across nasal epithelial barriers for systemic and direct nose-to-brain transport. We previously developed a modified CPP system termed Glycosaminoglycan-binding Enhanced Transduction (GET) that improves insulin delivery across gastrointestinal epithelium. It contains a membrane docking sequence to promote cellular interactions (P21), a cationic polyarginine domain to stimulate uptake (8R) and an endosomal escaping sequence to maximize availability for onward distribution (LK15). It is synthesized as a single 44-residue peptide (P21-LK15-8R; PLR). Methods: The current research used in vitro assays for a novel exploration of PLR’s ability to improve the transport of two contrasting peptides, insulin (51 residues, net negative charge) and oxytocin (9 residues, weak positive charge) across an RPMI 2650 human nasal epithelial cell barrier cultured at the air–liquid interface. Results: PLR enhanced insulin transcytosis over a 6 h period by 7.8-fold when used at a 2:1 molar ratio of insulin/PLR (p < 0.0001 versus insulin alone). Enhanced oxytocin transcytosis (5-fold) occurred with a 1:10 ratio of oytocin/PLR (p < 0.01). Importantly, these were independent of any impact on transepithelial electrical resistance (TEER) or cell viability (p > 0.05). Conclusions: We advocate the continued evaluation of insulin–PLR and oxytocin–PLR formulations, including longer-term assessments of ciliotoxicity and cytotoxicity in vitro followed by in vivo assessments of systemic and nose-to-brain delivery.

30 July 2025 in Neuroscience Applied
Verified
Journal Article
Open access
AMAsad Malik
Asad Malik
SMShannon N. Millard
Shannon N. Millard
AFAilidh Finlayson
Ailidh Finlayson
ABAmy Beckenstrom
Amy Beckenstrom
AAAbigail B Abrahams
Abigail B Abrahams
GDGerard R. Dawson
Gerard R. Dawson
The aims of the Reward Task Optimisation Consortium (RTOC) study (Bilderbeck et al., 2020) were to explore the validity, reliability, and feasibility of a battery of reward processing tasks for the development of new treatments for anhedonia. We report our findings from the Grip Strength Effort Task (GSET), an effort-based decision-making task in which participants chose to either perform easy trials that required less physical effort for low monetary reward or hard trials that required more effort for potentially larger rewards. Thirty-seven participants with schizophrenia (SZ), 40 with major depressive disorder (MDD), and 59 age- and sex-matched healthy controls were administered the task across four European sites. 19% of participants (8.5% HC, 27% SZ, 27.5% MDD) were ‘inflexible responders’ who always chose hard trials irrespective of the reward amount. MDD participants showed less willingness to exert physical effort for high reward than controls, when inflexible responders were excluded, but no statistically significant differences were observed between SZ participants and controls. Across all participants, willingness to exert effort for high reward negatively correlated with measures of anhedonia. Inflexible responders exhibited higher depressive symptoms and higher anticipation of punishment than other participants. Forty-three participants performed the GSET again after 3–5 weeks and moderate-to-high test-retest reliability was observed. Minimal site effects confirmed operational feasibility of the task in multi-site studies. We conclude that the GSET can provide objective behavioural biomarkers of reward processing dysfunction, but further investigation is needed to understand inflexible responding and its implications on the task's design and interpretation.

26 April 2026 in European Neuropsychopharmacology
Verified
Journal Article
Open access
SBSimon Braak
Simon Braak
MMMaarten Mennes
Maarten Mennes
TSTanja Su
Tanja Su
YPYolande Pijnenburg
Yolande Pijnenburg
GBGeor Bakker
Geor Bakker
Martien KasMartien Kas
Martien Kas
Cross-disorder research and replication of neuroimaging findings remains scarce. Social dysfunction is an early manifestation across diverse neuropsychiatric disorders that may relate to altered default mode network (DMN) integrity. This study aimed to replicate previous findings linking social dysfunction with diminished resting-state DMN functional connectivity and altered task-based DMN functional activation in response to emotional faces across schizophrenia (SZ), Alzheimer's disease (AD), and healthy controls (HC), and to extend these findings to major depressive disorder (MDD). Resting-state fMRI and task-based fMRI data on implicit facial emotional processing were acquired in an overlapping cohort (resting-state fMRI: N=167; SZ=32, MDD=44, AD=29, HC=62. Task-based fMRI: N=152; SZ=30, MDD=42, AD=26, HC=54). Additionally, mega-analyses (N=317 for resting-state fMRI; N=291 for task-based fMRI) of the current and a prior independent sample were conducted. Social dysfunction was indexed with the Social Functioning Scale (SFS) and the De Jong-Gierveld Loneliness (LON) scale. The association between higher mean SFS+LON social dysfunction scores and diminished DMN connectivity within the dorsomedial prefrontal cortex across SZ/AD/HC participants was replicated, and extended to MDD patients. Similar observations within the dorsomedial and rostromedial prefrontal cortex were found in the mega-analysis. Associations between social dysfunction and DMN activation in response to sad and happy faces were not replicated or found in the mega-analysis. To conclude, diminished dorsomedial prefrontal cortex DMN connectivity emerged as a transdiagnostic neurobiological marker for social dysfunction, suggesting a potential treatment target for precision medicine approaches. DMN functional responses to emotional faces may not be a sensitive biomarker for social dysfunction.